Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Presentation at Two Major Scientific Clinical Oncology Conferences in November

/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...

Related Keywords

Washington ,United States ,Westport ,Ottawa ,Ontario ,Canada ,Edna Kaplan ,Nilofer Azad ,Lilianl Siu ,Matthew Ingham ,Syed Mahmood ,Christianf Meyer ,Anthonyj Olszanski ,Matthewa Ingham ,Gilesf Whalen ,Michael Miller ,Jacob Thomas ,Bristol Myers Squibb ,Anthony El Khoueiry ,Diana Hanna ,Ianb Walters ,Merck Sharpe Dohme ,Lewish Bender ,Albirunir Razak ,Development Agreement ,Ontario Institute Of Cancer Research ,Ottawa Hospital Research Institute ,National Cancer Institute ,Society For Immunotherapy Of Cancer ,Bristol Myers Squibb Company ,Columbia University Medical Center ,Waltere Washington Convention Center ,Intensity Therapeutics Inc ,Rx Communications Group ,Vaccine Branch ,Connective Tissue Oncology Society Annual Meeting ,York Presbyterian Hospital Columbia University Medical Center ,Division Of Hematology ,Intensity Therapeutics ,Annual Meeting ,Assistant Professor ,New York Presbyterian ,Adult Subjects ,Metastatic Sarcomas ,Immune Response Data ,Locally Advanced ,Metastatic Solid ,Clinical Trials ,Friday November ,Convention Center ,Favorable Safety Profile ,Early Signs ,Advanced Soft Tissue Sarcoma ,Merck Sharpe ,Ontario Institute ,Cancer Research ,Cooperative Research ,Intensity Therapeutic ,Relations Contact ,Nc ,